Bevacizumab news

All news on Bevacizumab (also known as Avastin): plants, production capacities, investments and involved companies.

27 February 2026

Merck's KEYTRUDA Plus Paclitaxel Boosts Survival in Platinum-Resistant Ovarian Cancer

KEYTRUDA plus paclitaxel improves overall survival in platinum-resistant ovarian cancer, regardless of PD-L1 status, as shown in the KEYNOTE-B96 trial.
11 February 2026

Merck's KEYTRUDA and KEYTRUDA QLEX Approved for PD-L1+ Platinum-Resistant Ovarian Cancer

FDA approves KEYTRUDA regimens for platinum-resistant ovarian cancer, showing reduced disease progression and death risk in trials.
20 January 2026

Lilly's Sofetabart Mipitecan Gains FDA Breakthrough Status for Platinum-Resistant Ovarian Cancer

FDA grants Breakthrough Therapy status to sofetabart mipitecan for platinum-resistant ovarian cancer, based on promising Phase 1 results. Phase 3 trial underway.
19 October 2025

Raludotatug Deruxtecan Shows 50.5% Response in Platinum-Resistant Ovarian Cancer, Reports Daiichi Sankyo and Merck

Raludotatug deruxtecan achieved a 50.5% response rate in phase 2 for platinum-resistant ovarian cancer, with a 5.6 mg/kg dose selected for phase 3.

Who will be producing Bevacizumab in the future?

Find out with chemXplore Alpha

Learn more